Guardian Pharmacy Services (NYSE:GRDN) Posts Earnings Results, Beats Estimates By $0.03 EPS

Key Points

• Guardian Pharmacy Services beat quarterly expectations, reporting EPS of $0.29 versus the $0.26 consensus and revenue of $351.77 million versus $340.45 million expected.
• Management raised its 2026 outlook to revenue of $1.43 billion–$1.45 billion and adjusted EBITDA of $129 million–$131 million. Second-quarter adjusted EBITDA rose 19% to $29.7 million, supported by higher gross profit, favorable mix, productivity, and operating efficiencies.
• Shares rose 9.8% to $43.35, though investors face potential dilution and selling pressure from expected Class B conversions and the possible sale of up to 37 million employee- and insider-held Class A shares. IRA-related pricing reductions are also expected to weigh on reported second-half revenue.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) issued its quarterly earnings data on Thursday. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.26 by $0.03, FiscalAI reports. The business had revenue of $351.77 million for the quarter, compared to the consensus estimate of $340.45 million. Guardian Pharmacy Services had a return on equity of 31.45% and a net margin of 4.50%.

Here are the key takeaways from Guardian Pharmacy Services' conference call:

• Guardian raised its 2026 outlook, now expecting revenue of $1.43 billion–$1.45 billion and adjusted EBITDA of $129 million–$131 million, up from prior ranges of $1.40 billion–$1.42 billion and $123 million–$127 million, respectively.
• Second-quarter adjusted EBITDA increased 19% to $29.7 million, supported by an 18% increase in gross profit, favorable product and payer mix, purchasing leverage, labor productivity, and operating efficiencies.
• The company reported continued operating expansion, including high-single-digit growth in residents served and script volumes, the acquisition of Wellness Concepts in Virginia, and the launch of a greenfield pharmacy in Lexington, Kentucky.
• Guardian said IRA-related pricing reductions will continue to pressure reported revenue, with second-half revenue expected to decline year over year by a low-single-digit percentage; management expects underlying revenue growth to remain in the high-single digits and believes the margin impact has been mitigated.
• Approximately 13.5 million Class B shares are expected to convert into Class A shares in late September, and 35 million–37 million employee, management, and director-held Class A shares could become eligible for sale after the next trading window following the third-quarter results, creating a potential supply overhang.

Guardian Pharmacy Services Stock Up 9.8%

Shares of GRDN stock traded up $3.88 during mid-day trading on Friday, hitting $43.35. 1,045,061 shares of the stock were exchanged, compared to its average volume of 277,924. The firm has a fifty day moving average of $40.93 and a 200 day moving average of $37.09. Guardian Pharmacy Services has a 52-week low of $19.30 and a 52-week high of $47.02. The company has a market cap of $2.16 billion, a PE ratio of 42.09, a price-to-earnings-growth ratio of 2.59 and a beta of 0.10.

Institutional Trading of Guardian Pharmacy Services

A number of institutional investors and hedge funds have recently made changes to their positions in GRDN. Raymond James Financial Inc. acquired a new stake in shares of Guardian Pharmacy Services in the second quarter valued at about $43,000. Ameritas Investment Partners Inc. lifted its position in shares of Guardian Pharmacy Services by 26.5% in the third quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company's stock valued at $43,000 after acquiring an additional 345 shares in the last quarter. State of Wyoming purchased a new stake in shares of Guardian Pharmacy Services during the second quarter worth $58,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Guardian Pharmacy Services during the 3rd quarter valued at about $115,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Guardian Pharmacy Services by 48.0% in the second quarter. JPMorgan Chase & Co. now owns 6,027 shares of the company's stock valued at $128,000 after purchasing an additional 1,956 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GRDN. Oppenheimer increased their price objective on Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an "outperform" rating in a research note on Friday. Weiss Ratings raised shares of Guardian Pharmacy Services from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday. Wall Street Zen downgraded shares of Guardian Pharmacy Services from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Truist Financial upped their target price on Guardian Pharmacy Services from $43.00 to $47.00 and gave the company a "buy" rating in a research report on Wednesday, June 17th. Finally, Zacks Research lowered shares of Guardian Pharmacy Services from a "strong-buy" rating to a "hold" rating in a research report on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $43.83.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source